SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia — NSS

Negative Symptoms of Schizophrenia Clinical Trial

Official title:
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia

Status Withdrawn

Clinical Trial Summary

To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Negative Symptoms of Schizophrenia
Schizophrenia

Clinical Trial Details

NCT number	NCT01234298
Study type	Interventional
Source	Takeda
Contact
Status	Withdrawn
Phase	Phase 3
Start date	January 27, 2012
Completion date	February 24, 2014

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05985993` - Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia	N/A
Not yet recruiting	`NCT06388551` - A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017	Phase 1
Completed	`NCT03397134` - Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia	Phase 3
Recruiting	`NCT04620460` - Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia	N/A